Navigation Links
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug

SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, announced today that it has entered into a collaboration and license agreement with Pfizer Inc. to develop and commercialize its Hepatitis C virus (HCV) compound, TT-033. The collaboration will focus on completing all necessary studies for submission of an investigational new drug application (IND), as well as clinical development and commercialization of TT-033.

"We are very pleased about forming a collaborative relationship with Pfizer, and are excited about being first in the industry to partner an expressed RNAi drug," said Sara M. Hall, Chief Executive Officer of Tacere. "We have made excellent progress in the research and preclinical development of TT-033, and are very happy to be joined by Pfizer at an important time in the program's development. Pfizer recognizes the potential of this first-in- class approach to provide a novel treatment option for HCV patients and we look forward to working with the team at Pfizer to advance TT-033."

Mike Catelani, Chairman, President and CFO of Tacere, stated, "We look forward to combining Pfizer's and Tacere's complementary capabilities to take TT-033 into the clinic. We are pleased that Pfizer has chosen to work with us in developing this potential single administration RNAi drug to aid in the fight against the global healthcare crisis of HCV."

Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical research and development efforts for TT-033. Pfizer will fund all aspects of the collaboration, including the preclinical development work and will have exclusive worldwide rights, excluding all Asian countries, to commercialize products that result from the collaboration.

During the initial phase of the collaboration, Pfizer will provide Tacere with funding in order to complete the necessary IND-enabling studies for TT-033. In addition, Tacere will be eligible to receive milestone payments through successful achievement of development, approval, and commercialization milestones resulting in total potential payments to Tacere of over $145 million. Upon commercialization of TT-033 Tacere would be entitled to receive royalties on net sales by Pfizer.

About TT-033

TT-033 is a novel therapeutic product containing three separate RNAi elements targeted against the Hepatitis C virus itself and entrapped in an AAV protein coat. AAV delivery methods have demonstrated clinical safety, and preclinical studies with TT-033 have shown the ability to penetrate hepatocytes (the site of HCV replication) at high levels following a single intravenous administration. In preclinical animal studies, this "cocktail in one drug" monotherapy targeted and cleaved the Hepatitis C virus itself at three different sites simultaneously without toxicity.

About Tacere Therapeutics, Inc.

Tacere is an innovative biotechnology company focused on developing therapeutics to treat serious infectious diseases using its proprietary knowledge in the development of RNAi therapeutics. Tacere is located in San Jose, California, USA and obtained its founding capital from Hokkaido Venture Capital of Sapporo, Japan. Its lead therapeutic compound is TT-033, an RNAi drug for the treatment of Hepatitis C. For additional information, please visit



Mike Catelani

Chairman, President & CFO

+1 408 839-1818


Gregory Tiberend

Richard Lewis Communications, Inc.

+1 212 827-0020 or 917 406-1880

SOURCE Tacere Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015  Kay Elledge, M.D., an ... American College of Obstetrics and Gynecology (FACOG) for ... establishing the Genuine Self Medical Laser Center where ... In recognition of Breast Cancer Awareness Month ... for MonaLisa Touch treatments initiated in ...
(Date:10/13/2015)... , Oct. 13, 2015  ContraVir Pharmaceuticals, ... "Company"), a biopharmaceutical company focused on the development ... the closing of its previously announced underwritten public ... and warrants to purchase up to 3,000,000 shares ... combined price to the public of $3.00. The ...
(Date:10/13/2015)... 13, 2015  Data Science Automation (DSA), a system integration ... new branch office in the United Kingdom ... Europe . The decision to open the ... local support of customers in the medical device industry throughout ... Branch Manager. "We have had tremendous success over the last ...
Breaking Medicine Technology:
(Date:10/13/2015)... PA (PRWEB) , ... October 13, 2015 , ... "My ... digging his fists into his infected cheeks," said an inventor from Platteville, Colo. "I ... their skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing ...
(Date:10/13/2015)... Nashville, Tennessee (PRWEB) , ... October 13, 2015 ... ... owned leader of anesthesia and pain management services, today announced its partnership with ... the partnership integrates data from disparate systems and organizes the data into an ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ... and workflow solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG ... Nevada. AXUG Summit, GPUG Summit and NAVUG Summit are independent user conferences designed ...
(Date:10/13/2015)... TEXAS (PRWEB) , ... October 13, 2015 , ... ... and solution provider of IBM software products, introduced a new company, RightSensorâ„¢ LLC, ... systems and data communications capability. RightSensorâ„¢ provides a fully-managed approach for customers ...
Breaking Medicine News(10 mins):